Bank of New York Mellon Corp Sells 37,736 Shares of United Therapeutics Corporation $UTHR

Bank of New York Mellon Corp reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 9.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 362,471 shares of the biotechnology company’s stock after selling 37,736 shares during the period. Bank of New York Mellon Corp owned about 0.80% of United Therapeutics worth $104,156,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of United Therapeutics by 0.3% in the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock worth $1,374,001,000 after purchasing an additional 15,312 shares during the last quarter. Assetmark Inc. lifted its holdings in United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after buying an additional 197,384 shares during the period. Dimensional Fund Advisors LP grew its position in shares of United Therapeutics by 0.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock worth $192,571,000 after buying an additional 4,145 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec grew its position in shares of United Therapeutics by 22.5% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company’s stock worth $147,278,000 after buying an additional 87,664 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of United Therapeutics by 46.1% during the first quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock valued at $143,381,000 after buying an additional 146,664 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $436.09, for a total transaction of $9,157,890.00. Following the completion of the transaction, the chief financial officer owned 8,118 shares in the company, valued at approximately $3,540,178.62. The trade was a 72.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $450.34, for a total value of $4,953,740.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at $16,563,955.54. This trade represents a 23.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 412,935 shares of company stock worth $173,677,147. 10.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent analyst reports. Oppenheimer lifted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Cantor Fitzgerald boosted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. HC Wainwright increased their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Wednesday, October 29th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $503.90.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $448.91 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $479.50. The firm has a 50-day moving average of $423.96 and a 200 day moving average of $343.56. The stock has a market cap of $19.33 billion, a P/E ratio of 17.01, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter in the prior year, the company earned $6.39 earnings per share. The business’s revenue was up 6.8% compared to the same quarter last year. Research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.